Tebotelimab is a PD-1/LAG-3 bispecific tetravalent DART molecule developed by Zaiding Pharmaceuticals for the treatment of advanced mucosal melanoma patients treated on the first line. In preclinical studies, it has been shown to have synergistic anti-tumor activity. This evidence concerns the gene LAG3 and melanoma.